152 related articles for article (PubMed ID: 35008570)
1. Combination of targeted therapy and immunotherapy in melanoma.
Blank CU; Hooijkaas AI; Haanen JB; Schumacher TN
Cancer Immunol Immunother; 2011 Oct; 60(10):1359-71. PubMed ID: 21847631
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A; Amaral T
Front Oncol; 2024; 14():1340408. PubMed ID: 38469235
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma.
Nat Cancer; 2024 Apr; 5(4):544-545. PubMed ID: 38336886
[No Abstract] [Full Text] [Related]
4. Combatting mucosal melanoma: recent advances and future perspectives.
Tyrrell H; Payne M
Melanoma Manag; 2018 Sep; 5(3):MMT11. PubMed ID: 30459941
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
Sergi MC; Filoni E; Triggiano G; Cazzato G; Internò V; Porta C; Tucci M
Curr Oncol Rep; 2023 Nov; 25(11):1247-1258. PubMed ID: 37773078
[TBL] [Abstract][Full Text] [Related]
6. Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.
Simiczyjew A; Wądzyńska J; Kot M; Ziętek M; Matkowski R; Hoang MP; Donizy P; Nowak D
J Cell Mol Med; 2023 Oct; 27(19):2995-3008. PubMed ID: 37679999
[TBL] [Abstract][Full Text] [Related]
7. Current Trends in Mucosal Melanomas: An Overview.
Santeufemia DA; Palmieri G; Miolo G; Colombino M; Doro MG; Frogheri L; Paliogiannis P; Capobianco G; Madonia M; Cossu A; Lo Re G; Corona G
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900152
[TBL] [Abstract][Full Text] [Related]
8. Review: The Key Factors to Melanomagenesis.
Jitian Mihulecea CR; Rotaru M
Life (Basel); 2023 Jan; 13(1):. PubMed ID: 36676131
[TBL] [Abstract][Full Text] [Related]
9. Case report: complete remission with crizotinib in
Cao J; Yu Y; Zhou Y; Ji Q; Qian W; Jia D; Jin G; Qi Y; Li X; Li N; Li T; Fang M; Jin H
Front Oncol; 2022; 12():942258. PubMed ID: 36338718
[TBL] [Abstract][Full Text] [Related]
10. Editorial to the Special Issue on Skin Cancer: The State of the Art.
Rutkowski P; Mackiewicz A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409164
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
12. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of mucosal melanoma.
Nassar KW; Tan AC
Semin Cancer Biol; 2020 Apr; 61():139-148. PubMed ID: 31655118
[TBL] [Abstract][Full Text] [Related]
14. Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.
Indini A; Roila F; Grossi F; Massi D; Mandalà M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008570
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K; Yamazaki N
Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
[TBL] [Abstract][Full Text] [Related]
16. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
